EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER)

Yusuke Sano iD, Kana Miyazaki iD, Motoko Yamaguchi iD, Senzo Taguchi iD, Ryunosuke Machida, Kota Kawabata, Haruhiko Fukuda, Kazuyuki Shimada iD, Hirokazu Nagai, Wataru Munakata iD, Dai Maruyama iD, Japan Clinical Oncology Group Lymphoma Study Group

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf202 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Yusuke Sano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, National Cancer Center Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Central nervous system (CNS) relapse is an uncommon yet lethal event in patients with DLBCL. Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisolone (pola-R-CHP) is a standard of care for patients with untreated DLBCL. In patients with DLBCL at high risk of CNS relapse, the intrathecal (IT) administration of methotrexate and cytarabine is widely adopted for CNS prophylaxis; however, the optimal treatment is unclear. The aim of this multicenter randomized phase III trial is to confirm the superiority of high-dose methotrexate administered during early cycles of pola-R-CHP in addition to IT chemotherapy for patients with untreated DLBCL at high risk of CNS relapse. A total of 390 patients from 52 institutions will be enrolled across a 4-year period. The primary endpoint is progression-free survival. This trial was registered in the Japan Registry of Clinical Trials as jRCTs031230505 [https://jrct.mhlw.go.jp/latest-detail/jRCTs031230505].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsHumansMethotrexateRituximabCyclophosphamideDoxorubicinRandomized Controlled Trials as TopicMalePrednisoloneFemaleCytarabineClinical Trials, Phase III as TopicAntibodies, Monoclonal, HumanizedInjections, SpinalMiddle AgedAdultAgedMulticenter Studies as TopicAntibodies, MonoclonalImmunoconjugates

Stichwörter der Autor:innen

central nervous systemdiffuse large B-cell lymphomaintrathecal injectionsmethotrexate

Substanzen

MethotrexateRituximabCyclophosphamideDoxorubicinPrednisoloneCytarabineAntibodies, Monoclonal, Humanizedpolatuzumab vedotinAntibodies, MonoclonalImmunoconjugates

Autor:innen und Institutionen

  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.
  • Department of Hematological Malignancies, Mie University Graduate School of Medicine, 2-174 Edobashi, Mie 514-8507, Japan.
  • Department of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
  • Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
  • Department of Hematology, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi 460-0001, Japan.

ORCID-Profile: Yusuke Sano, Kana Miyazaki, Motoko Yamaguchi, Senzo Taguchi, Kazuyuki Shimada, Wataru Munakata, Dai Maruyama

Förderung

  • Japan Agency for Medical Research and Development
  • National Cancer Center Research and Development Fund

Zitieren

APA

Sano, Y., Miyazaki, K., Yamaguchi, M., Taguchi, S., Machida, R., Kawabata, K., Fukuda, H., Shimada, K., Nagai, H., Munakata, W., Maruyama, D., & Japan Clinical Oncology Group Lymphoma Study Group (2025). Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf202

Vancouver

Sano Y, Miyazaki K, Yamaguchi M, Taguchi S, Machida R, Kawabata K, et al. Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER). Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf202

BibTeX
@article{Sano2025,
  author = {Sano, Yusuke and Miyazaki, Kana and Yamaguchi, Motoko and Taguchi, Senzo and Machida, Ryunosuke and Kawabata, Kota and Fukuda, Haruhiko and Shimada, Kazuyuki and Nagai, Hirokazu and Munakata, Wataru and Maruyama, Dai and Japan Clinical Oncology Group Lymphoma Study Group, Japan Clinical Oncology Group Lymphoma Study Group},
  title = {Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER)},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf202}
}
Kostenlos starten →